Lonza Houston, Inc., a part of Lonza specializing in viral gene and cell therapy manufacturing, and bluebird bio, Inc., a clinical-stage gene therapy company, have for severe genetic diseases and T cell-based immunotherapies for cancer, have entered into a strategic manufacturing agreement providing for the future commercial production of bluebird bio's Lenti-D and LentiGlobin drug products.

This agreement follows a successful multi-year clinical manufacturing relationship and provides bluebird bio with a path to commercial supply, including dedicated production suites within Lonza's facility. This facility is currently under construction for the clinical and commercial supply of viral vectors and virally modified cell therapy products.

Under this multi-year agreement, Lonza will complete the suite design, construction, and validation along with process validation prior to anticipated commercial launch.

Source: Lonza